

PRESS RELEASE

FOR IMMEDIATE RELEASE

**PHARMANIAGA STRENGTHENS MALAYSIA'S MEDICINE SECURITY WITH
RM281.7 MILLION INSULIN CONTRACT**

Key takeaways:

- *3-year nationwide human insulin supply contract to support public healthcare institutions across Malaysia.*
- *Represents approximately 70% of the Ministry of Health's total insulin tender volume*
- *Advancing local biopharmaceutical capabilities through our Vision One30*

SHAH ALAM, 28 May 2026 – Pharmaniaga Berhad (“Pharmaniaga” or “the Group”) continues to strengthen its position in Malaysia’s healthcare sector with the award of a significant contract to supply human insulin to public healthcare institutions nationwide, reinforcing its standing as a key player within the country’s pharmaceutical and healthcare ecosystem.

This latest milestone sees the Group’s wholly owned subsidiary, Pharmaniaga LifeScience Sdn. Bhd. (PLS), securing a three-year contract valued at RM281.7 million from the Ministry of Health (MOH) for the supply of human insulin to healthcare facilities across the country. The award reflects the Group’s established manufacturing capabilities, proven execution track record and continued alignment with national healthcare priorities.

The contract represents approximately 70% of the total tender volume, underscoring Pharmaniaga’s scale, operational readiness and capacity to support large-volume, nationwide supply requirements. It also strengthens the Group’s recurring revenue base within the public healthcare segment, while further enhancing visibility of earnings over the contract period.

Importantly, the award reinforces Pharmaniaga’s growing role within the biopharmaceutical segment, particularly in the production and supply of critical chronic disease treatments such as insulin. As demand for such therapies continues to rise,

the Group's capabilities in this segment position it to capture long-term growth opportunities, while contributing meaningfully to the development of a more resilient domestic pharmaceutical manufacturing ecosystem.

Pharmaniaga Managing Director, Dato' Zulkifli Jafar, said, "We would like to express our sincere appreciation to the Ministry of Health Malaysia for its continued confidence in Pharmaniaga's manufacturing capabilities, local expertise and facilities, particularly in supporting the development of domestic insulin production.

"We are honoured to contribute to the Ministry's healthcare priorities, while further strengthening our manufacturing and supply chain capabilities in service of the nation. This award reflects the strategic direction we have set under Vision ONE30, which focuses on advancing biopharmaceutical capabilities, reinforcing our generics leadership, enhancing logistics excellence and unlocking value from new growth areas to support long-term, sustainable growth," he added.

"This contract comes at a timely juncture, as ongoing geopolitical developments continue to highlight the importance of building a more resilient and self-reliant domestic pharmaceutical ecosystem. Strengthening local manufacturing capabilities, particularly for essential and chronic disease treatments such as insulin, will be critical in safeguarding national medicine security and ensuring sustainable access to treatment for the rakyat in the years ahead," he concluded.

-END-

About Pharmaniaga Berhad

Pharmaniaga is the pharmaceutical arm of the Boustead Holdings Berhad Group of Companies, with Boustead Holdings Berhad and the Armed Forces Fund Board as the Company's substantial shareholders. Listed on the Main Market of Bursa Malaysia Securities Berhad, Pharmaniaga's core businesses are generic pharmaceuticals manufacturing; research and development; marketing and sales; warehousing and distribution of pharmaceutical and medical products. With a vision to be the premier Malaysian pharmaceutical company, its operations are strengthened by five

manufacturing plants, as well as extensive logistics and distribution network in Malaysia and Indonesia. Pharmaniaga Group is positioned to be a regional player in the international pharmaceutical industry.

For more information, please visit <https://pharmaniaga.com/>.

Issued by Imej Jiwa Sdn Bhd on behalf of Pharmaniaga Berhad

[For further media inquiries please contact:](#)

Dato' Zuhri Iskandar Kamarzaman (Pharmaniaga)

E-mail: zuhri@pharmaniaga.com

Telephone number: 03-3342 9999 ext. 434

Elizabeth Tan (Imej Jiwa)

E-mail: elizabeth@imejjiwa.com | Mobile: +6012 207 0993